511 related articles for article (PubMed ID: 34830058)
1. Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development.
Samarelli AV; Masciale V; Aramini B; Coló GP; Tonelli R; Marchioni A; Bruzzi G; Gozzi F; Andrisani D; Castaniere I; Manicardi L; Moretti A; Tabbì L; Guaitoli G; Cerri S; Dominici M; Clini E
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830058
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Ballester B; Milara J; Cortijo J
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
4. Common molecular pathways targeted by nintedanib in cancer and IPF: A bioinformatic study.
C L; A C; L V; L B; d'Alessandro M ; P C; G S; F D; E B
Pulm Pharmacol Ther; 2020 Oct; 64():101941. PubMed ID: 32896631
[TBL] [Abstract][Full Text] [Related]
5. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
Bamberg A; Redente EF; Groshong SD; Tuder RM; Cool CD; Keith RC; Edelman BL; Black BP; Cosgrove GP; Wynes MW; Curran-Everett D; De Langhe S; Ortiz LA; Thorburn A; Riches DWH
Am J Respir Crit Care Med; 2018 Oct; 198(7):914-927. PubMed ID: 29727583
[TBL] [Abstract][Full Text] [Related]
6. Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.
Gabasa M; Royo D; Molina-Molina M; Roca-Ferrer J; Pujols L; Picado C; Xaubet A; Pereda J
PLoS One; 2013; 8(6):e65445. PubMed ID: 23755232
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
[TBL] [Abstract][Full Text] [Related]
8. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
10. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
11. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.
Sava P; Ramanathan A; Dobronyi A; Peng X; Sun H; Ledesma-Mendoza A; Herzog EL; Gonzalez AL
JCI Insight; 2017 Dec; 2(24):. PubMed ID: 29263297
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer].
Xiao T; Bao J; Liu X; Huang H; Zhou H
Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):756-763. PubMed ID: 36167462
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis.
Velagacherla V; Mehta CH; Nayak Y; Nayak UY
Life Sci; 2022 Feb; 291():120283. PubMed ID: 34998839
[TBL] [Abstract][Full Text] [Related]
14. MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway.
Ballester B; Milara J; Montero P; Cortijo J
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204432
[TBL] [Abstract][Full Text] [Related]
15. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
16. Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts.
Bouros E; Filidou E; Arvanitidis K; Mikroulis D; Steiropoulos P; Bamias G; Bouros D; Kolios G
Pulm Pharmacol Ther; 2017 Oct; 46():78-87. PubMed ID: 28865842
[TBL] [Abstract][Full Text] [Related]
17. Tannic acid attenuates TGF-β1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-β signaling in lung epithelial cells.
Pattarayan D; Sivanantham A; Krishnaswami V; Loganathan L; Palanichamy R; Natesan S; Muthusamy K; Rajasekaran S
J Cell Physiol; 2018 Mar; 233(3):2513-2525. PubMed ID: 28771711
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of idiopathic pulmonary fibrosis.
Wolters PJ; Collard HR; Jones KD
Annu Rev Pathol; 2014; 9():157-79. PubMed ID: 24050627
[TBL] [Abstract][Full Text] [Related]
19. MUC1 intracellular bioactivation mediates lung fibrosis.
Milara J; Ballester B; Montero P; Escriva J; Artigues E; Alós M; Pastor-Clerigues A; Morcillo E; Cortijo J
Thorax; 2020 Feb; 75(2):132-142. PubMed ID: 31801904
[TBL] [Abstract][Full Text] [Related]
20. The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis.
Saito A; Horie M; Micke P; Nagase T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
